The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to ...

The announcement comes just a few months after WHO released its 2024 Bacterial Priority Pathogens List, which highlights the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...

Ig-Innovations Ltd is a brand new company with over 30 years experience in antibody production and immunoassay development. Confusing but true – the experience and expertise is in the people we employ ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from Chimagen Biosciences in a deal worth $850m. GSK said it plans to develop and ...

UCB has announced “encouraging data” from a phase 2a study of its investigational anti-tau antibody bepranemab in Alzheimer’s disease (AD) patients. The TOGETHER study has been evaluating the safety, ...

Principal Medical Writer, Dr Alexandra Loveday explores the importance of storytelling in health communications. Medical facts alone don’t change minds—stories do. Originating from the broader ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH), a progressive metabolic disease that affects ...

The launch of a new pharmaceutical product depends on a host of determinants and it just takes one factor to send the launch awry Just as the success of a rocket launch depends on a combination of ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...